Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2479 • 2013 ACR/ARHP Annual Meeting
Adalimumab Significantly Reduces Inflammation In Active Ankylosing Spondylitis: An Ultrasound Study
Zaiying Hu¹, Manlong Xu², Zetao Liao³, Zhiming Lin⁴ and Jieruo Gu⁵, ¹Rheumatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²THIRD AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSIT, Guangzho, China, ³Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ⁴Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ⁵Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China
Background/Purpose: To evaluate the feasibility of using power Doppler ultrasound (PDUS) to detect inflammation in sacroiliac joints and entheses after adalimumab (a TNF-alpha antagonist) treatment…
Abstract Number: 2354 • 2013 ACR/ARHP Annual Meeting
Drug Survival Rates Of Anti-Tumor Necrosis Factor Therapies In Patients With Rheumatoid Arthritis and Ankylosing Spondylitis
Dong-Jin Park¹, Kyung-Eun Lee¹, Ji-Hyoun Kang², Jeong-Won Lee², Tae-Jong Kim³, Yong-Wook Park¹ and Shin-Seok Lee⁴, ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Chonnam National University Medical School, Gwangju, South Korea, ³Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ⁴Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose: We investigated the compliance of Korean patients using anti-tumor necrosis factor (TNF) agents to treat rheumatoid arthritis (RA) and anklyosing spondylitis (AS), and identified…
Abstract Number: 1547 • 2013 ACR/ARHP Annual Meeting
How The Delay In Diagnosis Impacts On The Clinical, Functional and Radiographic Status Of Patients With Ankylosing Spondylitis. Is There a Window Of Opportunity?
luis Alejandro Cayetti¹, Emilce Schneeberger¹, Natalia Zamora², Fernando Sommerfleck² and Gustavo Citera², ¹Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: The delay in diagnosis has deleterious effects in patients with Rheumatoid Arthritis. This fact has not been fully investigated in patients with Ankylosing Spondylitis…
Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting
Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice
Gabriela Ávila¹, Sara Marsal¹, Arnald Alonso¹, Carolina Diaz², Estefanía Quesada-Masachs², María López-Lasanta¹ and Isabel Acosta³, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain, ³Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…
Abstract Number: 384 • 2013 ACR/ARHP Annual Meeting
Carotid Artery Plaques Are Associated With Coronary Atherosclerosis In Patients With Inflammatory Joint Diseases Independent Of Several Cardiovascular Risk Calculators
Silvia Rollefstad¹, Eirik Ikdahl², Inge C. Olsen³, Tore K. Kvien^4,5, Anne S. Eirheim², Terje R. Pedersen^4,6 and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Centre of Preventive Medicine, Oslo University Hospital-Ullevaal, Oslo, Norway
Background/Purpose: Patients with rheumatoid arthritis (RA) and carotid plaque (CP) have been shown to have increased risk of future acute coronary syndrome. We have established…
Abstract Number: 2489 • 2013 ACR/ARHP Annual Meeting
Spondyloarthritis-Associated Polymorphisms Of ERAP1 Are Correlated With Gene Expression, Protein Level and Enzymatic Activity Of The Amino-Peptidase
Félicie Costantino¹, Alice Talpin², Irini Evnouchidou³, Amir Kadi², Roula Said-Nahal⁴, Ariane Leboime⁵, Nelly Bonilla⁶, Franck Letourneur⁶, Tifenn Leturcq², Zeyna Ka², Peter van Endert³, Henri-Jean Garchon^2,7, Gilles Chiocchia^8,9 and Maxime A. Breban^2,7, ¹INSERM U987, Faculté des Sciences de la Santé Simone Veil, Montigny-le-Bretonneux, France, ²Institut Cochin - Université Paris Descartes - INSERM U1016 - CNRS (UMR 8104), Paris, France, ³INSERM U1013 - Université Paris Descartes - Sorbonne Paris Cité, Paris, France, ⁴Rheumatology Division, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁵Rheumatology Division, Ambroise-Paré Hospital AP-HP, Boulogne-Billancourt, France, ⁶INSERM U1016, Cochin Institute, Paris, France, ⁷Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁸Versailles Saint Quentin en Yvelines University, INSERM U987, UFR des Sciences de la Santé, Montigny-le-Bretonneux, France, ⁹Université Versailles-Saint Quentin, Montigny le Bretonneux, France
Background/Purpose: Endoplasmic reticulum aminopeptidase 1 (ERAP1) exerts a central role in antigen presentation making it an attractive candidate gene for inflammatory diseases. Several polymorphisms in…
Abstract Number: 2348 • 2013 ACR/ARHP Annual Meeting
Long Term Safety Of Intravenous Golimumab and Comparisons With Subcutaneous Golimumab In Rheumatologic Conditions: Results From The 120-Day Safety Report Of a Phase 3 Trial Of Intravenous Golimumab
Rene Westhovens¹, Clifton O. Bingham III², Michael E. Weinblatt³, Roy Fleischmann⁴, Edward C. Keystone⁵, Elizabeth C. Hsia⁶, Benjamin Hsu⁶, Lilianne Kim⁶, Surekha Mudivarthy⁶, Michael Mack⁷, Neil Goldstein⁶, Jürgen Braun⁸, Arthur Kavanaugh⁹, Alan M. Mendelsohn¹⁰ and Jonathan Kay¹¹, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁸PsAID taskforce, EULAR, Zurich, Switzerland, ⁹University of California San Diego, San Diego, CA, ¹⁰Immunology, Janssen Research & Development, LLC., Spring House, PA, ¹¹UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA
Background/Purpose: To describe safety profile of IV GLM in RA from the Ph3 GLM IV program. AE rates of interest are indirectly compared to…
Abstract Number: 1548 • 2013 ACR/ARHP Annual Meeting
Effect Of TNF Inhibitors On Bone Mineral Density In Patients With Ankylosing Spondylitis- a Systematic Review and Meta-Analysis
Nisha Nigil Haroon¹, Jeevitha Srighanthan², Nayef AL Ghanim³, Robert D. Inman^4,5,6,7,8,9 and Angela Cheung¹⁰, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Osteoporosis Program, University of Toronto, Ontario, ON, Canada, ³Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Research Institute. University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁸U of Toronto, Toronto, ON, Canada, ⁹Dept of Medicine/Rheumatology, The Arthritis Program, Toronto Western Hospital and Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with ankylosing spondylitis (AS) are susceptible to osteoporosis (OP) and have high fracture risk. Currently, no specific strategies are established to treat OP…
Abstract Number: 1417 • 2013 ACR/ARHP Annual Meeting
Lack Of Correlation Between Golimumab Exposure and Selected Safety Events Following Intravenous Or Subcutaneous Administration In An Integrated Analysis Of Phase 3 Data Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Or Ankylosing Spondylitis
Jocelyn H. Leu¹, Anna Beutler¹, Alan M. Mendelsohn², Sam Liao³, Hugh M. Davis¹, Honghui Zhou¹ and Zhenhua Xu¹, ¹Janssen Research & Development, LLC., Spring House, PA, ²Immunology, Janssen Research & Development, LLC., Spring House, PA, ³PharMax Research, Inc., Newport Beach, CA
Background/Purpose: For anti-TNFα agents, infections and malignancies are key safety concerns. It is unknown whether safety events are driven by peak (Cmax), trough (Cmin), average…
Abstract Number: 385 • 2013 ACR/ARHP Annual Meeting
Systemic Inflammation In Patients With Inflammatory Joint Disease Does Not Influence Statin Dose Needed To Obtain Low Density Lipoprotein Cholesterol Goal In Cardiovascular Prevention
Silvia Rollefstad¹, Eirik Ikdahl², Tore K. Kvien^3,4, Terje R. Pedersen^4,5, Ingar Holme⁶ and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Centre of Preventive Medicine, Oslo University Hospital-Ullevaal, Oslo, Norway, ⁶Department of biostatistics, epidemiology and health economics, Oslo University Hospital-Ullevaal, Oslo, Norway
Background/Purpose: There is a lipid paradox in rheumatoid arthritis (RA): despite low lipids influenced by systemic inflammation, there is an increased risk of cardiovascular (CV)…
Abstract Number: 2491 • 2013 ACR/ARHP Annual Meeting
Serum Levels Of Novel Noggin- and Sclerostin-Immune Complexes Are Elevated In Ankylosing Spondylitis
Florence W. Tsui¹, Hing Wo Tsui² and Robert D. Inman³, ¹Genetics and Development / Immunology, Toronto Western Research Institute UHN and University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute UHN, Toronto, ON, Canada, ³Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: Unravelling the basis of joint inflammation and ankylosis represents a major challenge in ankylosing spondylitis (AS) research. As noggin (NOG) and sclerostin (SOST) have…
Abstract Number: 2160 • 2013 ACR/ARHP Annual Meeting
The Journey to Diagnosis in As/Axial Spondyloarthritis – the Psychological Impact of Delay
Jane Martindale^1,2 and Lynne Goodacre², ¹Physiotherapy, Wrightington Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom, ²Faculty of Health and Medicine, Lancaster University, Lancaster, United Kingdom
Background/Purpose: It is not uncommon for 8 to 11 years to pass between symptoms onset and definitive diagnosis of AS/axial SpA (Gran 1997, Feldtkeller, 2003).…
Abstract Number: 1552 • 2013 ACR/ARHP Annual Meeting
Effective Prevention Of New Osteitis On Magnetic Resonance Imaging In Patients With Early Axial Spondyloarthritis During 3 Years Of Continous Treatment With Etanercept – Data Of The Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel³, Christian Althoff⁴, Denis Poddubnyy³, Joachim Listing⁵, Anja Weiss⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper¹⁰, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum, Berlin, Germany, ¹⁰Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin, Germany
Background/Purpose: In patients with early axial spondyloarthritis (SpA) with a disease duration of
Abstract Number: 1367 • 2013 ACR/ARHP Annual Meeting
Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry
ŽIga Rotar¹ and Matija Tomsic², ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia
Background/Purpose: Reactivation of latent tuberculosis infection (LTBI) is of concern in patients treated with TNFi. Conversely, TB chemoprophylaxis (CP) is time consuming, delays the initiation…
Abstract Number: 332 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Disease Among Patients With Psoriatic Arthritis Compared To Ankylosing Spondylitis (retrospective cohort study)
Zohair Abbas¹ and Marina N. Magrey², ¹Rheumatology, Case Western Reserve University at Metrohealth Medical Center, Cleveland, OH, ²Department of Medicine, Division of Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Both patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are at increased risk of cardiovascular disease (CVD). This increased risk is in part…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].